AI-powered polyp detector gains CE certification

PENTAX Medical, a division of the HOYA Group focused on endoscopic solutions, has received CE mark approval for its AI-powered polyp detector.

The solution, DISCOVERY, assists endoscopists by automatically seeking out signs of potential polyps. It was developed by a team at PENTAX Medical’s Augsburg, Germany-based research facility using data from approximately 300 clinical cases.

“The benefits for the customers are outstanding,” Wolfgang Mayer, managing director or research and development for PENTAX Medical Augsburg, said in a prepared statement. “Our vision was to bring artificial intelligence into the operating room in the most user-friendly way. We wanted to give doctors the possibility to use this exciting new technology to strive for a better clinical outcome and maximize the patient care.”

The company aims to begin launching DISCOVERY in early 2020.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.